What Happens During an Acute ILD Exacerbation?

An ILD exacerbation is a rapid, often life-threatening worsening of breathing in someone living with interstitial lung disease, typically unfolding over days to a few weeks. It sends many patients to intensive care with severe drops in blood oxygen, and in-hospital mortality remains high despite aggressive treatment. What makes these episodes so dangerous, and so difficult to manage, is that they can strike without a clear trigger, they mimic other emergencies, and the lung damage they cause is frequently irreversible. Understanding what provokes them, how they are recognized, and what treatments actually help is critical for anyone affected by ILD.

What Actually Happens in the Lungs During an Exacerbation

Interstitial lung diseases are a broad family of conditions where the tissue between the air sacs of the lungs becomes inflamed or scarred. In a stable state, this scarring (fibrosis) slowly stiffens the lungs and makes gas exchange harder. During an exacerbation, that slow process suddenly accelerates. Tissue biopsies show two main patterns of acute injury layered on top of the existing scarring. The more common and more dangerous pattern is called diffuse alveolar damage, where widespread inflammation floods the air sacs and their surrounding membranes. The second pattern resembles organizing pneumonia, where plugs of inflammatory tissue fill the small airways and air sacs.¹

This distinction matters practically because the organizing pneumonia pattern tends to respond better to treatment, while diffuse alveolar damage is more resistant to therapy.² Unfortunately, clinicians usually cannot biopsy a critically ill patient to determine which pattern dominates, so treatment decisions are made on clinical judgment and imaging patterns. This is one of the core frustrations of managing ILD exacerbations: the underlying pathology matters enormously for prognosis, but it is often unknowable in real time.

Known and Suspected Triggers

One of the unsettling features of ILD exacerbations is that many occur with no identifiable cause. But research has linked several categories of triggers to these events, and awareness of them can influence both prevention and early recognition.

Air Pollution

The strongest environmental evidence points to air pollution. A study following patients with idiopathic pulmonary fibrosis found that rising ozone and nitrogen dioxide levels in the preceding six weeks were significantly associated with exacerbation risk. For ozone, the hazard ratio was roughly 1.4 to 1.6 depending on the measure used, meaning a meaningful increase in risk with each jump in pollution exposure.³ A separate time-series study in Beijing found that fine particulate matter, sulfur dioxide, and nitrogen dioxide were all associated with increased IPF hospitalizations on high-pollution days, with sulfur dioxide showing a particularly notable link over longer exposure windows.⁴ For patients in polluted environments, air quality monitoring and limiting outdoor activity on bad days are reasonable precautions, though no trial has tested whether these measures prevent exacerbations.

Infections

Respiratory infections are an intuitive suspect, and they do appear to play a role in some cases, though the relationship is murkier than you might expect. A Japanese study looking specifically for viral infections in ILD exacerbation patients concluded that viruses were not frequently the trigger.⁵ Another study detected viruses in about one in five exacerbation patients. Those who tested positive had lower survival at 60 days (about 60% versus 83% for virus-negative patients), but when analyzed statistically, the viral infection itself did not independently predict death.⁶ The takeaway is that infections can coincide with and worsen exacerbations, but many exacerbations happen without any detectable infection, and proving causation has been elusive.

Gastroesophageal Reflux and Microaspiration

Acid reflux is strikingly common in people with ILD, and there has been longstanding concern that tiny amounts of stomach contents can be aspirated into the lungs, causing repeated low-grade injury that eventually tips into an exacerbation. This microaspiration hypothesis has led to widespread use of anti-reflux medications among ILD patients, though the evidence that this actually prevents exacerbations remains uncertain.⁷ Some clinicians treat reflux aggressively in their ILD patients as a precaution; others are more cautious, noting that long-term acid suppression carries its own risks.

Medical Procedures

Surgical lung biopsy, which is sometimes needed to diagnose ILD in the first place, can itself trigger an exacerbation. A study of patients undergoing video-assisted thoracoscopic surgery found that two deaths occurred from post-surgical exacerbations, both in IPF patients who already had significantly reduced lung function and required prolonged use of 100% oxygen during the procedure.⁸ This risk is one reason diagnostic approaches have shifted toward less invasive methods when possible, though biopsy remains essential in ambiguous cases.

The Diagnostic Challenge

When someone with ILD suddenly gets worse, the first task is figuring out whether this is a true exacerbation of the underlying disease or something else entirely. Several conditions can mimic an ILD exacerbation and require different, sometimes urgent, treatment.

Pulmonary embolism (a blood clot in the lungs) is particularly tricky in this population. ILD patients are at elevated clot risk, and the sudden breathlessness of a pulmonary embolism looks a lot like a flare. Standard scoring tools used in emergency departments to assess clot probability, such as the Wells score, do not reliably distinguish between the two in ILD patients. Researchers have found that D-dimer levels and total protein levels are better indicators: patients with pulmonary embolism had substantially higher D-dimer values than those without it.⁹ Heart failure and bilateral pneumonia also need to be ruled out, since treatment for each is fundamentally different.¹⁰

CT imaging is central to the workup. Clinicians look for new ground-glass opacities (hazy areas on the scan suggesting acute inflammation) superimposed on the patient’s known fibrotic changes. Bronchoscopy with fluid sampling may be performed to look for infection, though it carries its own risks in a critically ill patient with already compromised lungs.

Blood Markers That Track Severity

A blood protein called KL-6 has emerged as one of the more useful biomarkers in ILD. A meta-analysis found that KL-6 levels were, on average, about 545 units per milliliter higher during an acute exacerbation compared to stable disease. Higher KL-6 also predicted worse outcomes: patients who died had levels roughly 384 units higher than survivors, and elevated KL-6 roughly doubled the risk of death from ILD.¹¹

However, KL-6 has limitations. In patients with chronic hypersensitivity pneumonitis, KL-6 levels rose significantly during exacerbation episodes compared to measurements taken a month earlier, but another common marker, SP-D, did not change in a meaningful way across the same time points. And neither KL-6 nor SP-D levels during the exacerbation itself reliably distinguished survivors from non-survivors in that population.¹² So while KL-6 trends are useful for spotting flares and tracking disease trajectory broadly, no single blood test gives clinicians a reliable crystal ball for an individual patient’s outcome during an acute episode.

Treatment During an Exacerbation

There is no treatment for ILD exacerbation that is backed by a large randomized controlled trial, which is a sobering reality for such a serious condition. Management is largely based on observational data, expert consensus, and extrapolation from related diseases.

Corticosteroids

High-dose corticosteroids are the backbone of acute treatment, aimed at suppressing the runaway inflammation in the lungs. Evidence from emergency department admissions found that patients who received prednisolone at doses above 1 mg per kilogram of body weight had significantly better survival than those who received lower doses, at least in the overall ILD population and specifically in non-IPF forms of ILD. In IPF specifically, the survival benefit did not reach statistical significance.¹³ The need for mechanical ventilation within the first three days was one of the strongest predictors of death, and patients whose oxygen levels were better at presentation fared better regardless of treatment. Pulse-dose steroids (very high intravenous doses for a few days followed by a taper) are common practice, though the optimal dose and duration remain debated.

Immunosuppressive and Combination Therapies

For patients whose exacerbation is tied to an autoimmune or connective tissue disease, additional immunosuppression may be considered. Rituximab, a drug that depletes certain immune cells, has been used in combination with plasmapheresis (a procedure that filters the blood) and intravenous immunoglobulin, with some reports suggesting faster improvement in oxygen needs.¹⁴ But the picture is not uniformly encouraging. In patients with anti-MDA5 antibody-positive dermatomyositis, a particularly aggressive autoimmune condition, this triple combination therapy still failed to save most patients who had very high ferritin levels, with eight out of ten dying within a few months.¹⁵ That finding underscores a recurring theme: preventing the initial exacerbation may matter more than trying to reverse it once it is underway.

Oxygen and Ventilatory Support

Maintaining adequate oxygen is a minute-by-minute challenge. High-flow nasal cannula systems, which deliver warm humidified oxygen at high rates, have shown promise compared to traditional non-invasive positive-pressure ventilation. One small study reported 30-day mortality of 23% in patients treated with high-flow nasal cannula versus 63% in those receiving conventional non-invasive ventilation, a striking difference even if the study was too small to be definitive.¹⁶ Whether mechanical ventilation (intubation) actually changes the course of an exacerbation remains an open question. It may help buy time for patients who are candidates for lung transplantation, but for others, it often serves only to prolong the dying process.¹⁷

Can Exacerbations Be Prevented

Antifibrotic medications, particularly nintedanib, have drawn attention for their potential to reduce exacerbation risk. A meta-analysis confirmed that nintedanib reduces the risk of acute exacerbations in IPF, and both nintedanib and pirfenidone show similar effects on overall survival.¹⁸ A national database study in Japan went further, finding that patients already on nintedanib who were hospitalized for an exacerbation had substantially lower in-hospital mortality (odds ratio about 0.43) and shorter hospital stays (roughly 31 days versus 38 days) compared to those not on the drug.¹⁹ Whether this reflects a direct protective effect of the drug during the exacerbation itself or the benefit of having slowed disease progression beforehand is unclear, but either way, it supports the case for staying on antifibrotic therapy.

Beyond medications, managing modifiable risk factors helps. Keeping up with vaccinations, treating reflux, monitoring air quality, and avoiding unnecessary surgical procedures on already-compromised lungs are all common-sense strategies, though none has been tested in a dedicated prevention trial.

How Exacerbations Differ Across ILD Types

Exacerbations are best studied in IPF, the most common form of fibrosing ILD, but they occur across the entire ILD spectrum, including disease related to autoimmune conditions, hypersensitivity reactions, and sarcoidosis. The clinical features differ in ways that affect management.

A comparison between patients with connective tissue disease-related ILD and those with IPF found some notable differences. The autoimmune group tended to have better preserved lung function before the exacerbation and less honeycombing on imaging, yet they showed more inflammatory markers (higher white blood cell counts, higher C-reactive protein) at the time of the acute episode. They also had a longer delay between hospital admission and start of exacerbation treatment, averaging four days compared to one day for IPF patients. Despite these differences, survival was similarly poor in both groups.²⁰ That delay in treatment for the autoimmune group may reflect the diagnostic difficulty: when the ILD is associated with rheumatoid arthritis or lupus, an exacerbation can easily be mistaken for a disease flare affecting other organs, and the lung component may not be recognized immediately.

A Genetic Angle

Researchers have started looking at whether some patients are genetically predisposed to exacerbations. A gene called MUC5B, which encodes a mucus-producing protein in the airways, has been linked to ILD risk generally. In a study of patients with rheumatoid arthritis-related ILD, those carrying MUC5B variants had a higher risk of acute exacerbation or death, with a hazard ratio of about 2.3. Among patients who also showed a specific scarring pattern on imaging, the association was even stronger, with MUC5B mutations linked to a significantly shorter time to exacerbation or death.²¹ This was a small, exploratory study, and the multivariate analysis fell just short of significance, so it is far from settled. But it hints that genetic testing could eventually help identify patients who need more aggressive monitoring or earlier preventive treatment.

After the Exacerbation

Surviving an ILD exacerbation does not mean returning to a pre-flare baseline, but the picture is not always as bleak as feared. A study of six-month survivors found no statistically significant decline in lung function tests compared to measurements taken around the time of the exacerbation itself.²² That does not mean function was good in absolute terms, since many patients were already significantly impaired, but it suggests that those who survive the acute event may stabilize rather than spiral downward. The same study found that being rehospitalized after the initial discharge predicted poor long-term prognosis, making it an important signal for clinicians and patients alike.

The psychological and practical toll is substantial. Many patients with ILD end up dying in hospital settings, often with a high burden of tests and life-prolonging interventions, and low engagement with palliative care or advance care planning. This pattern has been documented across multiple countries, and it underscores the importance of having early conversations about goals of care, long before an exacerbation strikes, so that decisions in a crisis reflect the patient’s actual wishes rather than default hospital protocols.

The Financial Burden

ILD exacerbations are expensive. A U.S. claims database analysis found that patients who experienced exacerbations had total monthly healthcare costs of about $17,500, compared to roughly $11,700 for matched ILD patients without exacerbations. ILD-related inpatient admissions were nearly double in the exacerbation group.²³ A separate analysis of IPF patients specifically found that exacerbations leading to hospitalization cost about $14,700 per event on average, and nearly three-quarters of patients had at least one exacerbation-related urgent outpatient visit during a single year of follow-up.²⁴

Globally, annual direct costs of ILD vary enormously by country, ranging from roughly $1,600 per patient in South Korea to over $177,000 in the United States, with hospitalization and medication costs accounting for the vast majority of spending.²⁵ The financial strain compounds the medical one: exacerbations push patients into more frequent hospitalizations, more intensive monitoring, and higher drug costs, often at a stage of illness when they are least able to manage those burdens.

Experimental Approaches on the Horizon

Researchers are testing a few novel strategies. One that has gained attention, particularly in Japan, is direct hemoperfusion with a polymyxin B-immobilized fiber column, a blood-filtering technique originally developed for severe sepsis. In a small study of ILD exacerbation patients, the procedure improved oxygen levels and reduced inflammatory markers like interleukin-6 and C-reactive protein.²⁶ Whether those laboratory improvements translate into longer survival is not yet known. It is an example of the broader challenge in this field: interventions that look promising on paper-thin evidence face a long road to proving their worth in the kind of rigorous trials that would change clinical practice. For now, the treatment landscape for ILD exacerbations remains one where prevention and early recognition carry more weight than any single rescue therapy.